SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Biotech Valuation
An SI Board Since February 1999
Posts SubjectMarks Bans Symbol
52157 680 3 CRSP
Emcee:  Biomaven Type:  Moderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
50953FGEN Ph3 for pamrevlumab in IPF posted today. The only other serious Ph3 going atticus4paws35/17/2019
50952Stanford study discovers blocking a protein molecule on the blood-brain-barrier biocqr25/16/2019
50951That's what a randomized trial is all about. Sometimes in addition to pure rBiomaven-5/13/2019
50950Isn't it also true that the health status of individual patients on dialysisArt Bechhoefer-5/13/2019
50949There will be a publication in a high-profile journal (likely NEJM) later this yBiomaven-5/13/2019
50948Thank you for your thoughts. I am not sure what to expect in the near term. Wikeokalani'nui-5/13/2019
50947So I think this is the bottom line from the FGEN call - what Leerink says here: Biomaven25/13/2019
50946There are several issues here involving the FDA in regard to FGEN. The worrisomArt Bechhoefer-5/13/2019
50945Agree. if fgen language is indeed constrained by lawyers etc , it is obvious to linhtu-5/12/2019
50944 >>Neff reiterated that the NDA filing was going to happen this Sept/Oct (JamesK-5/12/2019
50943FGEN - In hindsight the April $35/40 put options buyers understood the state of semi_infinite -5/10/2019
50942The call was frustrating, but also informative. Are analysts and traders ignoriArt Bechhoefer15/10/2019
50941It was a frustrating call to listen to. Only FGEN really knows where ground truatticus4paws15/10/2019
50940They might have said something like, while we have no agreement with the FDA on mouton29-5/10/2019
50939I have to admit I still haven't heard or seen the call, but what I've reA.J. Mullen-5/10/2019
50938This is from a Merrill Lynch report this morning on AstraZeneca FGEN call had lCpi366325/10/2019
50937With these results and difficult interpretation is fgen a buy here or is it neceCpi3663-5/10/2019
50936How FGEN could have been clearer IMHO: Non-inferior MACE+ period. We can'atticus4paws-5/10/2019
50935no pre-specified analysis - FDA wants to go on totality of data. It would have DaveAu25/10/2019
50934No, that language is good. Street is concerned that they didn't echo it inBiomaven15/10/2019
50933I think the EMA agreed to a prespecified non-inferiority margin for MACE + but tmouton2915/9/2019
50932Also, if one looks at the entire market and the reaction to the latest tariff thArt Bechhoefer-5/9/2019
50931Listening to the entire CC, I understood that the drug works better, in terms ofArt Bechhoefer-5/9/2019
50930Thanks to both you and Tuck. Compounding my confusion, the language I quoted reA.J. Mullen-5/9/2019
50929tuck, I think you must mean to say 'never an agreed upon NI interval for Nonquidditch15/9/2019
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News